Keyword Connections

tacrolimus

Journals

37

1 PloS one

2 Medicine

3 Transplantation

4 journal of chromatography b, analytical technologies in the biomedical and life sciences

5 Journal of pharmaceutical and biomedical analysis

6 Therapeutic drug monitoring

7 British journal of clinical pharmacology

8 acta paediatrica (oslo, norway : 1992)

9 american journal of transplantation : official journal of the american society of transplantation and the american society of transplant surgeons

10 the british journal of dermatology

11 BMJ

12 revista chilena de pediatria

13 ecotoxicology (london, england)

14 journal of cosmetic dermatology

15 Journal of clinical immunology

16 Journal of the American Academy of Dermatology

17 clinical transplantation

18 international journal of clinical pharmacy

19 the australasian journal of dermatology

20 jama dermatology

21 bmc nephrology

22 pediatric dermatology

23 dermatologic surgery : official publication for american society for dermatologic surgery [et al]

24 Transplantation proceedings

25 lasers in surgery and medicine

26 journal of cutaneous medicine and surgery

27 dermatologic therapy

28 european journal of dermatology : ejd

29 expert opinion on pharmacotherapy

30 expert opinion on drug metabolism & toxicology

31 biology of blood and marrow transplantation : journal of the american society for blood and marrow transplantation

32 Veterinary dermatology

33 microsurgery

34 postepy dermatologii i alergologii

35 scandinavian journal of clinical and laboratory investigation

36 therapie

37 Transplantation and cellular therapy

Research Groups

0

No Research Group Connected

Bibliographies

123

1 Effect of CYP3A5 genotype on hospitalization cost for kidney transplantation.

2 Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients.

3 Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.

4 Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).

5 Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.

6 Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.

7 Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.

8 Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

9 [Level of evidence for therapeutic drug monitoring of everolimus].

10 Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study.

11 Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

12 Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients.

13 Mycophenolate blood level monitoring: recent progress.

14 Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.

15 Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis

16 the routine practice of therapeutic drug monitoring - some of the results of work in the system of chi

17 analysis on optical coherence tomography in vogt-koyanagi-harada syndrome before and after therapy

18 pomada de tacrolimo 0,1% no tratamento de vitiligo: série de casos tacrolimus 0,1% ointment in the treatment of vitiligo: a series of cases

19 unraveling nutritional regulation of tacrolimus biosynthesis in streptomyces tsukubaensis through omic approaches

20 tacrolimus associated posterior reversible encephalopathy syndrome – a case series and review

21 Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.

22 Physicochemical, Pharmacodynamic and Pharmacokinetic Characterization of Soluplus Stabilized Nanosuspension of Tacrolimus.

23 Randomized Controlled Trial Assessing the Impact of Everolimus and Low Exposure Tacrolimus on Graft Outcomes in Kidney Transplant Recipients.

24 Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients.

25 Protocol-Based Nurse Coordinator Management of Ambulatory Tacrolimus Dosing in De Novo Renal Transplant Recipients - A Single Center Experience with a Large African American Population.

26 The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomised clinical trials.

27 Trichomegaly induced by topical tacrolimus for the treatment of periorbital vitiligo: A brief report of a new adverse effect.

28 Q-Switched Alexandrite Laser and Topical 20% Monobenzyl Ester of Hydroquinone Removal of Tacrolimus-Induced Repigmentation (After Complete Depigmentation With 20% Monobenzyl Ether of Hydroquinone).

29 A multicentre, randomized, split face and/or neck comparison of 308-nm excimer laser and 0·1% tacrolimus ointment for stable vitiligo plus intramuscular slow-releasing betamethasone for active vitiligo.

30 A preliminary study of fractional CO laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo.

31 Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo.

32 Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus.

33 Accelerated repigmentation of vitiligo after an irritant reaction following occlusion dressing with topical tacrolimus.

34 Utility of dermoscopy for evaluating the therapeutic efficacy of tacrolimus ointment plus 308-nm excimer laser combination therapy in localized vitiligo patients.

35 Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo.

36 Unwanted lentigines after topical tacrolimus for vitiligo.

37 A multicentre, randomized, split face and/or neck comparison of 308-nm excimer laser and 0·1% tacrolimus ointment for stable vitiligo plus intramuscular slow-releasing betamethasone for active vitiligo

38 The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomised clinical trials

39 Clinical efficacy of fractional carbondioxide laser combined with tacrolimus ointment in treatment of localized vitiligo

40 Unwanted lentigines after topical tacrolimus for vitiligo

41 Duration of response in vitiligo lesions after narrowband UVB phototherapy combined with tacrolimus ointment

42 Efficacy of tacrolimus plus narrowband ultraviolet B phototherapy versus narrowband ultraviolet B phototherapy alone in the treatment of vitiligo

43 To assess the efficacy of topical 0.03% tacrolimus ointment in the treatment of vitiligo

44 Effectiveness and safety of topical tacrolimus in treatment of vitiligo

45 Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: A single-blinded pilot study

46 Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy

47 A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo

48 Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo

49 A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter

50 Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: A comprehensive literature review

51 The efficacy of 308 nm UV excimer light as monotherapy and combination therapy with topical khellin 4% and/or tacrolimus 0.1% in the treatment of vitiligo

52 Comparison of topical 0.03% tacrolimus with 0.05% clobetasol in treatment of vitiligo

53 A successful helium-neon laser and topical tacrolimus combination therapy in one child with vitiligo

54 Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo-Controlled Study

55 A Placebo-controlled Comparative Study of Topical Flocinolone Acetonide Ointment versus Topical 0.1% Tacrolimus Ointment in the Treatment of vitiligo Lesions of Upper Extremities

56 Effect of Topical Tacrolimus on Vitiligo in Children

57 Segmental vitiligo: A randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream

58 COMPARATIVE STUDY OF TOPICAL MOMETASONE FUROATE 0.1%, TOPICAL 0.03% TACROLIMUS, TOPICAL BASIC FIBROBLAST GROWTH FACTOR (bFGF) IN CHILDHOOD VITILIGO

59 Efficacy and tolerability of combined treatment with NB-UVB and topical tacrolimus versus NB-UVB alone in patients with vitiligo vulgaris: A randomized intra-individual open comparative trial

60 STUDY OF EFFICACY TOPICAL TACROLIMUS IN DIFFERENT DERMATOSES

61 Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy

62 Effect of 0.1% tacrolimus ointment in localized vitiligo: An open uncontrolled trial

63 Triple combination of systemic corticosteroids, excimer laser, and topical tacrolimus in the treatment of recently developed localized vitiligo

64 An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area

65 Efficacy of 0.1% topical tacrolimus with narrow band ultraviolet B phototherapy versus narrow band ultraviolet B phototherapy in vitiligo

66 The effectiveness of excimer laser on vitiligo treatment in comparison with a combination therapy of Excimer laser and tacrolimus in an Iranian population

67 Safety of 0.1% topical tacrolimus in the treatment of vitiligo

68 Vitiligo, NB-UVB and tacrolimus: Our experience in Naples

69 Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo

70 Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: A proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment

71 Topical tacrolimus is useful for avoiding suction-blister epidermal grafting depigmentation in non-segmental vitiligo: A case report

72 Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.

73 Tacrolimus-induced diabetic ketoacidosis with subsequent rapid recovery of endogenous insulin secretion after cessation of tacrolimus: A case report with review of literature.

74 Behavioral and immunotoxic effects of Prograf® (tacrolimus) in the male Siamese fighting fish.

75 A new HPLC-MS/MS method for simultaneous determination of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus for routine therapeutic drug monitoring.

76 Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids.

77 Retraction: Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients.

78 Tacrolimus area under the concentration versus time curve monitoring, using home-based volumetric absorptive capillary microsampling.

79 A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study.

80 Long-term Clinical Significance of Tacrolimus Trough Level at the Early Period After Kidney Transplantation.

81 Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors.

82 Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: a model-based meta-analysis approach.

83 Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.

84 Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients

85 Therapeutic potential of coenzyme Q<inf>10</inf> in mitochondrial dysfunction during tacrolimus-induced beta cell injury

86 Low-Dose Tacrolimus Prevents Dysregulated Peri-Conceptional Ovarian and Systemic Immune Cellular Homeostasis in Subjects with PCOS

87 Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection

88 Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy

89 Tacrolimus-loaded lecithin-based nanostructured lipid carrier and nanoemulsion with propylene glycol monocaprylate as a liquid lipid: Formulation characterization and assessment of dermal delivery compared to referent ointment

90 Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation

91 Targeted delivery of tacrolimus to T cells by pH-responsive aptamer-chitosan- poly(lactic-co-glycolic acid) nanocomplex

92 Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy

93 Periodontal microbiological status influences the occurrence of cyclosporine-a and tacrolimus- induced gingival overgrowth

94 Forced degradation of tacrolimus and the development of a UHPLC method for impurities determination

95 Therapeutic drug monitoring of cyclosporine and tacrolimus in Myanmar kidney transplant patients

96 Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis

97 Ginseng increases Klotho expression by FoxO3-mediated manganese superoxide dismutase in a mouse model of tacrolimus-induced renal injury

98 Influence of Tacrolimus on Depressive-Like Behavior in Diabetic Rats Through Brain-Derived Neurotrophic Factor Regulation in the Hippocampus

99 Dermal delivery of the high-molecular-weight drug tacrolimus by means of polyglycerol-based nanogels

100 Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus

101 Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?